🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Louis Moore Bacon’s APGE Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+20,000 Shares
Current Position
20,000 Shares
$2.65 M Value

Louis Moore Bacon's APGE Position Overview

Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 20,000 shares of Apogee Therapeutics, Inc. (APGE) worth $2.65 M, representing 0.04% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Louis Moore Bacon has initiated a new position in APGE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Louis Moore Bacon's Apogee Therapeutics (APGE) Holding Value Over Time

Track share changes against reported price movement

Quarterly Apogee Therapeutics (APGE) Trades by Louis Moore Bacon

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +20,000 New Buy 20,000 $132.73

Louis Moore Bacon's Apogee Therapeutics Investment FAQs

Louis Moore Bacon first purchased Apogee Therapeutics, Inc. (APGE) in Q2 2026, acquiring 20,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Louis Moore Bacon has held Apogee Therapeutics, Inc. (APGE) for 1 quarters since Q2 2026.

Louis Moore Bacon's largest addition to Apogee Therapeutics, Inc. (APGE) was in Q2 2026, adding 20,000 shares worth $2.65 M.

According to the latest 13F filing for Q2 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 20,000 shares of Apogee Therapeutics, Inc. (APGE), valued at approximately $2.65 M.

As of the Q2 2026 filing, Apogee Therapeutics, Inc. (APGE) represents approximately 0.04% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.

Louis Moore Bacon's peak holding in Apogee Therapeutics, Inc. (APGE) was 20,000 shares, as reported at the end of Q2 2026.